StreetAlpha.app
Home › Stocks › AVR

Anteris Technologies Global Corp. (AVR)

Healthcare
$4.99
▼ −1.96%
LAST CLOSE · NOV 20

Anteris Technologies develops the DurAVR THV System, a heart valve for patients with aortic stenosis, for cardiologists and surgeons. It last closed at $4.99 on Nov 20, down 1.96% on the day. The next earnings report for AVR is expected around Thu, Feb 25, 2027, after the close. For the quarter ended Sep 2026, AVR reported EPS of -$0.28 on revenue of $519,000, with revenue up 21.0% from a year ago. Over its last 8 reports the stock moved an average of 4.8% the session after earnings. Over the last 12 months AVR insiders bought $40.5M of stock on the open market and sold $25.2M, according to SEC Form 4 filings.

AI Auto Pilots
Is AVR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AVR.

Key Stats

Last 12 months
Results
Revenue
$2.3M
+9.0% vs a year ago
Net income
−$108.1M
−4637.5% margin
EPS (diluted)
−$1.60
Free cash flow
−$93.5M
−4008.4% margin
Valuation
Market cap
$486.5M
97.5M shares
P/E
–
No P/E while losing money
Price to sales
208.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$217.0M
At Sep 30
Shareholder equity
$226.8M
Shares outstanding
97.5M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $2.7M$2.7MFY2024FY2025: $1.9M$1.9MFY2025

From AVR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · After the close
Reported EPS
-$0.28
Quarter ended Sep 2026
Year ago EPS
-$0.62
Same quarter last year
Revenue
$519,000
+21.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.71Dec '24Mar 2025: -$0.61Mar '25Jun 2025: -$0.58Jun '25Sep 2025: -$0.62Sep '25Dec 2025: -$0.75Dec '25Mar 2026: -$0.28Mar '26Jun 2026: -$0.30Jun '26Sep 2026: -$0.28Sep '26Latest -$0.28
Revenue by quarter
Dec 2024: $536,000Dec '24Mar 2025: $556,000Mar '25Jun 2025: $618,000Jun '25Sep 2025: $429,000Sep '25Dec 2025: $310,000Dec '25Mar 2026: $494,000Mar '26Jun 2026: $1.0MJun '26Sep 2026: $519,000Sep '26Latest $519,000
How AVR moved after its last 8 reports
Average move the session after a report ±4.8%
Nov 10, 2026After the close+5.3%
Aug 11, 2026After the close−3.3%
May 13, 2026Before the open−2.5%
Feb 26, 2026After the close+2.7%
Nov 12, 2025After the close−2.6%
Aug 12, 2025Before the open+6.0%
May 13, 2025After the close−9.9%
Mar 12, 2025After the close−6.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on AVRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on AVR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AVR

Technical Analysis

AVR · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 15% below its 20 day and 33% below its 50 day average. It is 48% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 34), near oversold. The nearest support is the Pivot S1 at $4.88, and the nearest resistance the Pivot at $5.03.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 7.8%/day
Key levels
$11.0552 week high+121.4%
$7.73100 day average+54.9%
$7.37200 day average+47.7%
$6.6350 day average+32.9%
$6.25Swing high (Nov 12)+25.3%
$5.7520 day average+15.2%
$5.14Pivot R1+3.0%
$5.03Pivot+0.8%
$4.99Last close
$4.88Pivot S1−2.2%
$3.3052 week low−33.9%
Indicators
RSI (14)34.43Weak, oversold below 30Neutral
MACD-0.39Below its signal lineBearish
Stochastic8.2Near the bottom of its rangeOversold
ADX (14)30.4Trending down
Williams %R-92.7Oversold below −80, overbought above −20Oversold
CCI (20)-172.4Oversold below −100, overbought above 100Oversold
Rate of change−12.3%Change over 10 sessionsBearish
ATR (14)$0.39Typical daily range, 7.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AVR

What happened before

See how AVR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for AVRHow many large options trades hit AVR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

AVR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼58 buying vs 68 selling
  • ▼Held by funds -3.6 pts
  • ●Funds holding +0
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1361360.0%
In funds' top 1023−33.3%
Held by funds67.2%70.8%−3.6 pts
New / increased20 / 3828 / 56−31.0%
Reduced / sold out47 / 2135 / 17+30.8%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AVR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AVR Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$40.5M5 buys · 2 insiders
Sold$25.2M8 sales · 1 insider
2026-01 bought $28.8M2026-06 bought $102K2026-07 sold $9.6M2026-08 sold $15.6M2026-10 bought $11.7MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 6L1 Capital Pty Ltd10% ownerBuy272,695$7.18$2.0M
Oct 5L1 Capital Pty Ltd10% ownerBuy884,809$7.58$6.7M
Oct 1L1 Capital Pty Ltd10% ownerBuy397,226$7.62$3.0M
Aug 28L1 Capital Pty Ltd10% ownerSale7,800$8.83$69K
Aug 11L1 Capital Pty Ltd10% ownerSale627,659$9.22$5.8M
Aug 6L1 Capital Pty Ltd10% ownerSale174,721$8.10$1.4M
Every insider buy and sale for AVR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See AVR insider trades →

From SEC Form 4 filings by AVR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AVR is in one of them and how their past AVR trades turned out.

AVR in the AI portfolios
Loading…

AVR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AVR in an article yet. Here's the latest on the wider market.

AVR in the news

About Anteris Technologies Global

Anteris Technologies is a structural heart company based in Eagan, Minnesota. Its main product is the DurAVR THV System, a single piece transcatheter heart valve for patients with aortic stenosis, a narrowing of the aortic valve. The valve is delivered with a balloon expandable system and is intended for use by heart specialists and surgeons who treat these patients. The DurAVR is not yet approved for commercial sale in the United States or Europe and is being studied in clinical trials.

Headquarters
Eagan, MN